Egypt Immuno-Oncology Research Review Issue 7

In this issue:
  -  Tisa-cel vs. axi-cel in relapsed/refractory DLBCL
  -  Liso-cel vs. standard of care, as second-line, in relapsed/refractory LBCL
  -  PROs for axi-cel, as second-line, in LBCL
  -  Anti-CD19 CAR T-cells for B-cell ALL with CNS involvement
  -  Next-day manufacture of anti-CD19 CAR T-cells for B-cell ALL
  -  Long-term follow-up of anti-BCMA + CD19 CAR T-cells in myeloma
  -  Disparities in immune checkpoint inhibitor trials
  -  Mosunetuzumab for relapsed/refractory follicular lymphoma
  -  Teclistamab in relapsed/refractory myeloma
  -  OS with brentuximab vedotin in stage III–IV Hodgkin lymphoma

Download PDF Subscribe